Video

Single administration of intracameral bimatoprost implant: IOP lowering, safety

Author(s):

David Hutton,Alex Delaney-Gesing
Conferences|AAO

Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.

Michael R. Robinson, MD, vice president, Global Therapeutic Area Head, Ophthalmology at Allergan, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.

See more AAO coverage here

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Vikas Chopra, MD, at AAO 2024: The role of MIGS in earlier intervention and safer techniques
Related Content
SpyGlass Pharma completes enrollment in Phase I/II study of its long-term drug delivery platform for glaucoma and ocular hypertension
November 19th 2024

SpyGlass Pharma completes enrollment in Phase I/II study of its long-term drug delivery platform for glaucoma and ocular hypertension

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

AAO 2024: Ocular imaging in the emergency department can provide timely, accurate diagnosis
November 1st 2024

AAO 2024: Ocular imaging in the emergency department can provide timely, accurate diagnosis

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function
October 22nd 2024

Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function

AAO 2024: New drug shows promise as first to protect vision in patients with dry AMD
October 21st 2024

AAO 2024: New drug shows promise as first to protect vision in patients with dry AMD

© 2024 MJH Life Sciences

All rights reserved.